Skip to main content
. 2019 Oct 10;9:14627. doi: 10.1038/s41598-019-51217-6

Figure 4.

Figure 4

Antiproliferative effect of an FGFR inhibitor and 3D structures of FGFR4. (A) Antiproliferative effect of ASP5878 on (a) G636C-FGFR4/BaF3 and (b) G636C-FGFR4/3T3 cells. Three independent experiments were performed in triplicate, and representative data are shown as the mean ± SD. Geometric mean IC50 values and 95% confidence intervals (CIs) were determined from three independent experiments. (B) Mice engrafted with G636C-R4/3T3 cells were orally administered ASP5878 (3 mg/kg, once daily). Tumour volumes were measured, and data are shown as the mean ± SEM (n = 5). Tumour volumes on day 7 were compared between the ASP5878-treated and vehicle control groups (Student t test). (C) 3D models of FGFR4 wild-type and G636C with ASP5878. (a) Overview of 3D models of the kinase domain of FGFR4 (cyan, wild-type; pink, G636C). The heavy atoms of ASP5878, G636 or C636 are represented as sticks. (b) Close-up of the binding site of ASP5878.